Has the MOPP era ended?

Has The Era Of Slow Growth For Prescription Drug Spending Ended?

In the period 2005-13 the US prescription drug market grew at an average annual pace of only 1.8 percent in real terms on an invoice price basis (that is, in constant dollars and before manufacturers' rebates and discounts). But the growth rate increased dramatically in 2014, when the market expanded by 11.5 percent-which raised questions about future trends. We determined the impact of manufac...

Asthma: the epidemic has ended, or has it?

All truths are easy to understand once they are discovered; the point is to discover them. A sthma, a chronic inflammatory lung condition with acute episodes of bronchoconstriction and exacerbation, is associated with considerable patient morbidity, a diminution of productivity, and an increase in health-care utilization. Throughout the 1980s and 1990s, there was a clear perception that asthma ...

Has the Euro Era Facilitated Inflation Convergence?

This paper investigates the long-run convergence of national inflation rates in the European Union. The application of a new test is proposed that involves unit root testing of the first principal component based on national-EU inflation differentials. Using inflation data based on harmonized consumer price indices for 1999-2007, the first principal component is stationary. This suggests that a...

Prednisone in MOPP chemotherapy for Hodgkin's disease.

High remission rates have been produced by MOPP (mustine, vincristine, procarbazine, and prednisone) chemotherapy in patients with advanced Hodgkin's disease, but the prednisone component has caused adverse effects in patients who have undergone radiotherapy. The remission rates and length of remission were reviewed in 211 patients with Hodgkin's disease who received chemotherapy either with or...

Phase I trials in oncology: a new era has started.